^
Association details:
| Biomarker: | RAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.
Published date:
01/18/2022
Excerpt:
Combined selinexor with pembrolizumab demonstrated higher disease control rates and prolonged overall survival in patients with chemotherapy-refractory advanced/metastatic CRC with RAS mut vs RAS wt tumors....These patients would not have been eligible for anti-PD-1 mAb therapy because their tumors were not MSI-high, suggesting that the combination may be active in RAS mut CRC.
DOI:
10.1200/JCO.2022.40.4_suppl.110
Source:
Title:
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Published date:
09/13/2021
Excerpt:
This phase I/II, open-label study enrolled pts with advanced/metastatic CRC...Pts were treated using weekly oral SEL 80 mg and pembro 200 mg IV every 3 weeks....Median overall survival has not been reached for pts with CRC with RAS mut and is 6.1 months for those with RAS wt...Disease control was greater among pts with RAS mut versus wt tumors.
